Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Jan 31, 2023 6:46pm
196 Views
Post# 35258182

RE:RE:RE:RE:Waiting...

RE:RE:RE:RE:Waiting...
Hello Westcoast, there were indeed issues with the trial design and even though they had a top investigator helping them it did not work. Problem is that people were being removed from the trial that should not have been as a result of a higher than normal temperatures in the patients which is actually a sign of the virus working and many of those patients were removed. Also at that time they were not allowed to as we now do, break the trial up into different segments and basiclally do what they call data mining which is where we get a lot of our information now. Regardless the trial was not successful for many of the above reasons.
Lets just get this moving and get the trial going, if negotiations are taking so long almost makes me think partnership as a buyout should move quicker. But what do we all know, the speculation is most intersting for sure but the waiting it all out is killing me.
<< Previous
Bullboard Posts
Next >>